GSK announced on Friday that it had sold its remaining shares in Haleon, its former consumer healthcare subsidiary, at a unit price of 324 pence, raising nearly 1.25 billion pounds (around 1.46 billion euros).

With this placement, made at a discount of around 2.5% to last night's closing price, GSK has now fully exited Haleon.

For the record, GSK held a stake of over 12.9% in Haleon at the time of the demerger and IPO of its former subsidiary as an independent listed entity in July 2022, but had gradually reduced its shareholding in the meantime.

Since its IPO, Haleon shares have appreciated by around 13%.

Following this placement, Haleon shares were down 0.5% on Friday morning on the Patis stock exchange, while GSK was down 0.8%.

Copyright (c) 2024 All rights reserved.